Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2022-06-03 00:00:00 ET · period of report 2022-06-01 · accession 0001567619-22-012311 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-03 | 2022-06-01 | ARQT | Leonard Keith R | Dir | A - Grant | $0.00 | +4,312 | 4,312 | New | $0 |
| D | 2022-06-03 | 2022-06-01 | ARQT | Leonard Keith R | Dir | A - Grant | $0.00 | +11.8K | 11.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-01 | A | A | 4,312 | $0.00 | 4,312 | D | — | — | (F1) Includes 4,312 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-06-01 | A | A | 11,796 | $0.00 | 11,796 | D | $20.29 · — to 2032-06-01 | 11,796 Common Stock | (F3) The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 1, 2022. |